PMID: 18729010Aug 30, 2008Paper

Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia

Current Opinion in Investigational Drugs
Iain C Macdougall

Abstract

Hematide is a synthetic peptide-based erythropoiesis-stimulating agent that is being developed by Affymax Inc and Takeda Pharmaceutical Co Ltd. Hematide is undergoing phase III clinical trials for anemia.

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.